We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Simvastatin Reduces Adiponectin Levels and Insulin Sensitivity

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00546182
First Posted: October 18, 2007
Last Update Posted: October 18, 2007
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Gachon University Gil Medical Center
  Purpose
We hypothesized simvastatin may reduce adiponectin levels and insulin sensitivity in overweight hypercholesterolemic patients.

Condition
Hypercholesterolemia

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Phase 4 Study of Simvastatin That Affects Insulin Sensitivity

Resource links provided by NLM:


Further study details as provided by Gachon University Gil Medical Center:

Primary Outcome Measures:
  • simvastatin may reduce adiponectin levels and insulin sensitivity in overweight hypercholesterolemic patients

Study Start Date: January 2004
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   25 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Study Population
overweight hypercholesterolemic patients
Criteria

Inclusion Criteria:

  • Low-density lipoprotein cholesterol levels more than 100 and body mass index more than 23.0

Exclusion Criteria:

  • Patients with overt liver disease
  • Chronic renal failure
  • Hypothyroidism, myopathy
  • Uncontrolled diabetes
  • Severe hypertension, stroke
  • Acute coronary events
  • Coronary revascularization within the preceding 3 months, or
  • Alcohol abuse.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00546182


Locations
Korea, Republic of
Gil Medical Center, Gachon University
Incheon, Korea, Republic of, 405760
Sponsors and Collaborators
Gachon University Gil Medical Center
Investigators
Principal Investigator: Kwang K Koh, MD,PhD Gachon University Gil Medical Center
  More Information

Publications:
ClinicalTrials.gov Identifier: NCT00546182     History of Changes
Other Study ID Numbers: GMC-200405
First Submitted: October 17, 2007
First Posted: October 18, 2007
Last Update Posted: October 18, 2007
Last Verified: October 2007

Keywords provided by Gachon University Gil Medical Center:
Lipophilic statins
Insulin resistance
hypercholesterolemic patients

Additional relevant MeSH terms:
Hypercholesterolemia
Insulin Resistance
Hyperlipidemias
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases
Hyperinsulinism
Glucose Metabolism Disorders
Insulin
Simvastatin
Hypoglycemic Agents
Physiological Effects of Drugs
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors